On a 1.0mL syringe, each line represents a larger volume increment, reducing precision but allowing draws up to 100 units
Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, Attenuates Obesity-Induced Inflammation in the Nodose Ganglion, Hypothalamus, and Skeletal Muscle of Mice
FDA approval is expected in late 2027 or early 2028, with commercial launch following 13 months later
Better You Rx is located outside of the USA and does not accept US-based insurance
10% weight loss guarantee has eligibility requirements
What to Expect: GLP-1 Side Effect Reality Check Nausea : The most frequently reported side effect, typically more prominent when first starting or increasing doses Vomiting : Less common than nausea, possible during initial adjustment Diarrhea or constipation : Can occur alongside other GI effects Reduced appetite : A therapeutic effect that helps with weight loss, but can sometimes feel uncomfortable Many patients report that side effects decrease significantly after the first few weeks, and severe reactions requiring discontinuation are relatively rare